 <h1>Thorazine Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>chlorpromazine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about chlorpromazine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Thorazine.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to chlorpromazine: oral tablets, parenteral injection</i></p><h3>Warning</h3><p><ul>
Increased Mortality in Geriatric Patients with Dementia-related Psychosis
<li>
Geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.&lt;sup&gt;101&lt;/sup&gt; &lt;sup&gt;105&lt;/sup&gt; &lt;sup&gt;106&lt;/sup&gt; &lt;sup&gt;n&lt;/sup&gt;</li></ul></p><ul>
Increased Mortality in Geriatric Patients with Dementia-related Psychosis
<li>
Geriatric patients with dementia-related psychosis treated with antipsychotic agents are at an increased risk of death.&lt;sup&gt;101&lt;/sup&gt; &lt;sup&gt;105&lt;/sup&gt; &lt;sup&gt;106&lt;/sup&gt; &lt;sup&gt;n&lt;/sup&gt;</li></ul><p>
<li>
Analyses of 17 placebo-controlled trials in geriatric patients mainly receiving atypical antipsychotic agents revealed an approximate 1.6- to 1.7-fold increase in mortality compared with that in patients receiving placebo.&lt;sup&gt;101&lt;/sup&gt; &lt;sup&gt;105&lt;/sup&gt; &lt;sup&gt;106&lt;/sup&gt; &lt;sup&gt;n&lt;/sup&gt;</li></p><p>
<li>
Most fatalities appeared to result from cardiovascular-related events (e.g., heart failure, sudden death) or infections (mostly pneumonia).&lt;sup&gt;105&lt;/sup&gt; &lt;sup&gt;106&lt;/sup&gt; &lt;sup&gt;n&lt;/sup&gt;</li></p><p>
<li>
Observational studies suggest that conventional or first-generation antipsychotic agents also may increase mortality in such patients.&lt;sup&gt;101&lt;/sup&gt; &lt;sup&gt;105&lt;/sup&gt; &lt;sup&gt;106&lt;/sup&gt;</li></p><p>
<li>
Antipsychotic agents, including chlorpromazine, are <i>not</i> approved for the treatment of dementia-related psychosis.&lt;sup&gt;101&lt;/sup&gt; &lt;sup&gt;105&lt;/sup&gt; &lt;sup&gt;106&lt;/sup&gt; &lt;sup&gt;n&lt;/sup&gt;</li></p><p></p><p>Side effects include:</p><p>Extrapyramidal reactions (e.g., Parkinson-like symptoms, dystonia, akathisia, tardive dyskinesia), drowsiness, dizziness, skin reactions or rash, dry mouth, orthostatic hypotension, amenorrhea, galactorrhea, weight gain.     </p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to chlorpromazine: compounding powder, injectable solution, oral capsule extended release, oral concentrate, oral syrup, oral tablet, rectal suppository</i></p><h3>General</h3><p>The most frequently reported side effects included drowsiness, sedation, dry mouth, and nasal stuffiness.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Mild leukopenia (up to 30%)</p><p><b>Common</b> (1% to 10%): Agranulocytosis, leukopenia, eosinophilia, hemolytic anemia, aplastic anemia, thrombocytopenia purpura, pancytopenia</p><p><b>Uncommon</b> (0.1% to 1%): Purpura, leukocytosis, coagulation defects<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Acute dystonia and/or dyskinesia typically were transitory, occurring more frequently in children and young adults within the first 4 days of treatment or after dose changes.</p><p></p><p>Akathisia usually occurred after patients were given large initial doses.</p><p></p><p>Autonomic dysfunction occurred as a symptom of neuroleptic malignant syndrome.</p><p></p><p>Convulsive seizures have occurred more frequently in patients with a history of seizures and/or with EEG abnormalities.</p><p></p><p>Momentary fainting occurred most commonly in patients after the first injection, with a lower frequency of occurrence in subsequent injections; patients given oral formulations rarely fainted after the initial dose.</p><p></p><p>Parkinsonism more commonly occurred in adults and elderly patients after weeks to months of treatment.</p><p></p><p>Sedation and somnolence occurred more frequently at the start of treatment.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Hypertonia, tardive dyskinesia, tardive dystonia, extrapyramidal syndrome, akathisia, parkinsonism, motor restlessness, drowsiness, convulsion/convulsive seizures (petit mal and grand mal), lowering of the seizure threshold, acute dyskinesia or dystonia</p><p><b>Uncommon</b> (0.1% to 1%): Cerebral edema, epileptic fits, neuroleptic malignant syndrome, myasthenia gravis, abnormality of cerebrospinal fluid proteins</p><p><b>Frequency not reported</b>: Lethargy, akinesia, hyperkinesia, autonomic dysfunction, tremor, drooling, pill rolling motion, cogwheel rigidity, shuffling gait, rhythmical involuntary movements of the tongue/face/mouth/jaw, involuntary movements of the extremities, fine vermicular movements of the tongue, dizziness, headache, momentary fainting, pseudo-parkinsonism, mask-like facies</p><p><b>Postmarketing reports</b>: Cerebrovascular adverse events<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Dry mouth, constipation, nausea, obstipation, adynamic ileus, atonic colon</p><p><b>Uncommon</b> (0.1% to 1%): Paralytic ileus</p><p><b>Postmarketing reports</b>: Ischemic colitis, intestinal perforation/fatal intestinal perforation, gastrointestinal (GI) necrosis/fatal GI necrosis, intestinal obstruction, tongue protrusion, difficulty swallowing, necrotizing colitis/fatal necrotizing colitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p>Altered consciousness occurred as a symptom of neuroleptic malignant syndrome.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Anxiety, mental confusion, agitation, excitement, aggravation of schizophrenic symptoms</p><p><b>Uncommon</b> (0.1% to 1%): Nightmares, dysphoria, catatonic excitement, mental dulling/slowing</p><p><b>Rare</b> (0.01% to 0.1%): Psychotic symptoms, catatonic-like states</p><p><b>Frequency not reported</b>: Insomnia, altered mood, altered consciousness<sup>[Ref]</sup></p><h3>Ocular</h3><p>Accommodation disorder was related to anticholinergic effects of this drug.</p><p></p><p>Eye deposits occurred in the anterior segment of the eye from drug accumulation; however, the deposits usually did not have impact on sight.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Blurred vision, photophobia, corneal/eye deposits, miosis and mydriasis</p><p><b>Uncommon</b> (0.1% to 1%): Optic atrophy, lens opacities, pigmentary retinopathy, precipitation/aggravation of narrow angle glaucoma</p><p><b>Frequency not reported</b>: Oculogyric crisis, ocular changes, accommodation disorder<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary retention/hesitancy, priapism, ejaculation disorders/impotence</p><p><b>Uncommon</b> (0.1% to 1%): Amenorrhea, incontinence, lactation and moderate breast engorgement (female patients)</p><p><b>Frequency not reported</b>: Galactorrhea, oligomenorrhea, erectile dysfunction, female sexual arousal disorder<sup>[Ref]</sup></p><p>Lactation and breast engorgement in female patients occurred with large doses.</p><p></p><p>Urinary retention was linked to anticholinergic effects of this drug.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Contact dermatitis, photosensitivity/photosensitivity reaction, urticarial/maculopapular/petechial or edematous reaction</p><p><b>Uncommon</b> (0.1% to 1%): Skin pigmentation, exfoliative dermatitis, toxic epidermal necrolysis</p><p><b>Frequency not reported</b>: Allergic dermatitis, skin rashes</p><p><b>Postmarketing reports</b>: Angioneurotic edema<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Impaired glucose tolerance, hyperglycemia, weight gain</p><p><b>Uncommon</b> (0.1% to 1%): Hypoglycemia, water retention</p><p><b>Postmarketing reports</b>: Hypertriglyceridemia, hyponatremia, increased appetite<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Orthostatic/postural hypotension, ECG changes (electrocardiogram QT prolongation, ST depression, U-Wave and T-Wave changes)</p><p><b>Uncommon</b> (0.1% to 1%): Arrhythmias, hypertensive crisis, AV block, ventricular tachycardia/tachycardia, QT prolongation and fibrillation, edema, labile blood pressure</p><p><b>Frequency not reported</b>: Ventricular fibrillation, Torsade de pointes, cardiac arrest, sudden cardiac death, profound hypotension, peripheral edema, venous embolism, deep vein thrombosis, cardiac arrhythmias (including ventricular and atrial arrhythmias)<sup>[Ref]</sup></p><p>Cardiac arrest may be related to dose as well as preexisting conditions (e.g., cardiac disease, old age, hypokalemia, concurrent tricyclic antidepressants).</p><p></p><p>Hypertensive crisis occurred after abrupt withdrawal of treatment.</p><p></p><p>Orthostatic hypotension occurred more frequently in elderly and/or volume depleted patients, and was more likely to occur with IM administration.</p><p></p><p>Sudden cardiac death may be related to causes of cardiac origin.<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Hypothalamic effects, hyperprolactinemia/elevated prolactin levels</p><p><b>Uncommon</b> (0.1% to 1%): Gynecomastia, profuse sweating, false positive pregnancy tests, inappropriate antidiuretic hormone secretion<sup>[Ref]</sup></p><h3>Other</h3><p>Hyperthermia occurred as a symptom of neuroleptic malignant syndrome.</p><p></p><p>Mild fevers have occurred in patient who received large doses intramuscularly.</p><p></p><p>Sudden death may be related to causes of cardiac origin, asphyxia, convulsions, or hyperpyrexia.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Paradoxical reactions, impaired thermoregulation/temperature regulation disorder</p><p><b>Uncommon</b> (0.1% to 1%): Hyperthermia, hypothermia, malignant hyperpyrexia</p><p><b>Frequency not reported</b>: Sudden death, jitteriness, neonatal drug withdrawal syndrome<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Nasal congestion/stuffiness, respiratory depression</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea</p><p><b>Frequency not reported</b>: Bronchospasm, pulmonary embolism/fatal pulmonary embolism</p><p><b>Postmarketing reports</b>: Asthma, laryngeal edema, throat tightness, asphyxia (failure of the cough reflex)<sup>[Ref]</sup></p><h3>Local</h3><p>Contact sensitization has occurred in individuals who frequently handled this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Injection site pain, injection abscess</p><p><b>Uncommon</b> (0.1% to 1%): Contact skin sensitization<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Positive systemic lupus erythematosus (SLE) cells, antinuclear antibody (ANA) positive/raised ANA titer<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Cholestatic jaundice</p><p><b>Uncommon</b> (0.1% to 1%): Liver injury, fatal liver injury, cholestatic/hepatocellular or mixed liver injury</p><p><b>Frequency not reported</b>: Progressive hepatic fibrosis<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Uncommon</b> (0.1% to 1%): Elevated creatine phosphokinase, muscular rigidity/rigidity, myoglobinuria/rhabdomyolysis</p><p><b>Rare</b> (0.01% to 0.1%): Systemic lupus erythematosus </p><p><b>Frequency not reported</b>: Torticollis, trismus</p><p><b>Postmarketing reports</b>: Prolonged, abnormal muscle contractions, neck muscle spasms<sup>[Ref]</sup></p><p>Elevated creatine phosphokinase, muscular rigidity, and myoglobinuria/rhabdomyolysis are symptoms of neuroleptic malignant syndrome.</p><p></p><p>Rigidity occurred as a symptom of neuroleptic malignant syndrome.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Uncommon</b> (0.1% to 1%): Glycosuria, acute renal failure<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Severe allergic reactions/allergic reactions</p><p><b>Rare</b> (0.01% to 0.1%): Anaphylactic/anaphylactoid reactions</p><p><b>Frequency not reported</b>: Angioedema<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_3">3. "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA. </p><h2>More about Thorazine (chlorpromazine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>En Espa√±ol</li>
<li>35 Reviews</li>
<li>Drug class: phenothiazine antiemetics</li>
<li>FDA Alerts (3)</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hiccups</li>
<li>Light Sedation</li>
<li>Mania</li>
<li>Nausea/Vomiting</li>
<li data-more-config-id="list-data-resources-conditions">... +5 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>